Drug Channels

NOVEMBER 9, 2022

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2023. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia. The webinar will last 90 minutes to accommodate audience questions.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

MARCH 30, 2023

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. So far, it appears that PBMs are neither preferring Amgen's Humira biosimilar nor embracing the low-list/low-rebate version.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

Drug Discovery World

APRIL 4, 2024

To address these challenges, the speakers have developed and implemented better-performing and higher throughput technologies.

Biosimilars 130

Biosimilars Drugs 130

Drug Discovery World

APRIL 4, 2024

In this webinar the speakers will discuss: Method of testing the interaction of a lead biosimilar antibody candidate versus a commercially available antibody Develop an assay to determine the level of binding activity Utilisation of the assay in QC lot release Register for free.

Biosimilars 130

Biosimilars Drugs 130

FDA Law Blog: Biosimilars

JUNE 10, 2024

Director Larry Houck will participate as a panelist focusing on this timely topic in the Food and Drug Law Institute’s (“FDLI’s”) “High Time for a Change: Implications of DEA’s Proposed Marijuana Rescheduling” webinar June 12, 2024, 2:00-3:30 pm ET.

Regulations 59

Regulations Drugs Research 59

Drug Channels

JULY 20, 2022

In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. Cut through the steamy summer haze with our refreshing selection of articles and insights.

Biosimilars 98

Biosimilars Pharmacy Drugs Marketing 98

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The webinar will be 90 minutes to accommodate audience questions.

Marketing 97

Marketing Biosimilars Drugs Hospitals 97

Drug Discovery World

APRIL 25, 2024

To address these challenges, our speakers have developed and implemented better performing and higher throughput technologies.

Biosimilars 130

Biosimilars Drugs 130

Drug Channels

APRIL 19, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. An ironic postcript: Less than two months after my article was published, Cigna CEO David Cordani bragged about the cost savings from "aggressive adoption" of biosimilars.

Biosimilars 98

Biosimilars Production FDA Drugs 98

Drug Discovery World

APRIL 18, 2024

To address these challenges, our speakers have developed and implemented better performing and higher throughput technologies.

Biosimilars 130

Biosimilars Drugs 130

Drug Channels

MAY 30, 2023

Speaking of PBMs, be sure to join me for my new live video webinar, PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding , on June 23, 2023, from 12:00 p.m. I recommend that you follow me on LinkedIn, because the quality of comments is much higher than they are on Twitter.) to 1:30 p.m.

Biosimilars 98

Biosimilars Hospitals Pharmacy Drugs 98

Drug Channels

DECEMBER 17, 2020

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Drug Channels Outlook 2021. Conveniently for HHS, ASPE's analysis stopped before the biosimilar boom began. The biosimilar market is finally beginning to fulfill its promise. Drug pricing perceptions always seem to lag reality.

Biosimilars 52

Biosimilars Marketing Regulations FDA 52

FDA Law Blog: Biosimilars

JUNE 24, 2024

HPM) Director Dara Katcher Levy will present an informative webinar on the newly released AMCP Format for Formulary Submissions version 5.0. To register for this insightful webinar, visit AMCP Learn. This afternoon Hyman, Phelps & McNamara, P.C.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Discovery World

APRIL 10, 2024

In this webinar the speakers will discuss: Method of testing the interaction of a lead biosimilar antibody candidate versus a commercially available antibody Develop an assay to determine the level of binding activity Utilisation of the assay in QC lot release Register for free.

Biosimilars 100

Biosimilars Drugs 100

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The Outlook 2022 marks our third annual outlook webinar. Broadcast live on December 17, 2021.

Specialty Pharmacies 94

Specialty Pharmacies Biosimilars Pharmacy Drugs 94

Drug Channels

MARCH 31, 2022

Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa. CVS Health takes the red pill.

Biosimilars 98

Biosimilars Pharmacy Drugs 98

Drug Channels

MAY 29, 2024

Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Join my nearly 56,000 LinkedIn followers for daily links to neat stuff. Click here to learn more and reserve your spot at the June 21 event.

Biosimilars 52

Biosimilars Drugs Marketing 52

Drug Channels

FEBRUARY 21, 2024

Just another IRA-inflicted hit for biosimilars? Join me on April 5 for DCI's next live webinar: Drug Channel Implications of the Inflation Reduction Act. The warped incentives don't stop there. As always, I encourage you to share your own thoughts with the Drug Channels community on social media. P.S. Want to learn more?

Biosimilars 98

Biosimilars Drugs Government Production 98

FDA Law Blog: Biosimilars

MAY 15, 2024

In this webinar you’ll learn: Significant changes between the proposed and final rule How the current enforcement discretion approach for LDTs will affect you A timeline for the rollout of the rule’s five phases Get your questions answered by the experts during the live Q&A Don’t delay, click here to register today!

Laboratories 59

Laboratories Government FDA 59

Drug Channels

APRIL 20, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBM Industry Update: Trends, Controversies, and Outlook. Below, I highlight five observations about this year’s lists, including unexplainable differences in how PBMs handle specialty drugs, biosimilars, and insulin.

Biosimilars 98

Biosimilars Pharmacy Production Drugs 98

FDA Law Blog: Biosimilars

MAY 22, 2023

HP&M”) invites you to join Director Larry Houck for a free webinar demystifying DEA inspections by providing an understanding of controlled substance accountability audits, the importance of conducting mirror reviews, and mock DEA-style internal inspections. Hyman, Phelps & McNamara, P.C. (“HP&M”)

International 40

International Drugs 40

FDA Law Blog: Biosimilars

MAY 3, 2023

HP&M”) invites you to join Director Larry Houck for a free webinar demystifying DEA inspections by providing an understanding of controlled substance accountability audits, the importance of conducting mirror reviews and mock DEA-style internal inspections. The webinar will share additional valuable inspection tips.

International 52

International Drugs 52

FDA Law Blog: Biosimilars

SEPTEMBER 12, 2023

In this webinar you’ll learn: How employees diverted controlled substances — their methods are constantly evolving What red flags were missed DEA inspection priorities Safeguards to minimize internal diversion Best practices for maximizing diversion detection Mr.

Hospitals 49

Hospitals Pharmacy Compliance Government 49

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2023

In this webinar you’ll learn: How employees diverted controlled substances — their methods are constantly evolving What red flags were missed DEA inspection priorities Safeguards to minimize internal diversion Best practices for maximizing diversion detection Mr.

Hospitals 45

Hospitals Pharmacy Compliance Government 45

FDA Law Blog: Biosimilars

MARCH 12, 2023

Please see detailed information in the attached flyer , including a link to register for our free webinar. John will present on considerations and his learned perspective for the future of teleprescribing. We hope you join us!

Regulations 98

Regulations Government FDA Drugs 98

FDA Law Blog: Biosimilars

APRIL 12, 2023

will present a webinar entitled “ Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC.” On Thursday, April 20, from 1:30-3:00pm, John Claud of Hyman, Phelps & McNamara, P.C.

FDA 52

FDA Compliance Science Production 52

Agency IQ

MARCH 1, 2024

There are also some product-specific bioequivalence guidelines open for comment, along with concept papers proposing the development of materials on the topics of biosimilar development and non-inferiority comparisons in clinical trials.

Regulations 40

Regulations Biosimilars Clinical Trials Production 40

Agency IQ

OCTOBER 20, 2023

BsUFA III regulatory science pilot offers progress report, fields stakeholder criticisms and questions This week, FDA and its grantees briefed stakeholders on the status of research projects funded through the Biosimilar User Fee Act (BSUFA III) Regulatory Science Pilot Program. Developing biosimilars is an extensive and expensive process.

Science 40

Science Biosimilars FDA Production 40

Alta Sciences

JUNE 9, 2023

Altasciences has the clinical capabilities to demonstrate the biosimilarity of drug products between Asian and non-Asian populations by comparing the pharmacokinetics of the investigational drug in both ethnic groups, providing a safe strategy to save time and money. Download your copy today. In this complimentary webinar , Mel B.

Drug Development 40

Drug Development Clinical Trials Biosimilars Pharmacokinetics 40

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Biosimilars 98

Biosimilars Drugs Hospitals 98

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Biosimilars 97

Biosimilars Drugs Hospitals 97

Agency IQ

MARCH 29, 2024

This will include a number of conferences, webinars, and training sessions, as well as a long-awaited EMA workshop on psychedelics. regulatory framework Webinar/ Seminar ( OPEN ) EMA 4/17/2024 4/17/2024 CEP 2.0: regulatory framework Webinar/ Seminar ( OPEN ) EMA 4/17/2024 4/17/2024 CEP 2.0:

Regulations 40

Regulations Production Biosimilars Clinical Trials 40

Drug Discovery World

MARCH 29, 2023

He pointed out that Europe was the first region to approve biosimilars. In the same webinar, Emer Cooke, EMA Executive Director, countered, in relation to regional drug approvals, “Faster isn’t necessarily better. You can compare timelines. I would claim that the variety offered here is on a par with other regions.”

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

Drug Channels

NOVEMBER 22, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy FDA Biosimilars 98

Agency IQ

MAY 3, 2024

Many of these are webinars and/or trainings sessionsfor new digital platforms. This month will also see several large, multi-day conferences hosted by public and private stakeholders. Start Date End Date Event Event Type Organization 4/30/2024 4/30/2024 Seminar No.

Regulations 40

Regulations Clinical Trials Production Biosimilars 40